CTXR faces a rare three-way convergence. Short interest hit 29.6% of float. The options market just turned sharply bullish. And earnings drop today.
Short interest rose 26.2% in one week to 29.6% of free float. That's the highest level since May and represents a sustained build — positions have climbed roughly 38% over the past month.
Cost to borrow stands at 49.6%. That's up 146% over 30 days. Borrowing CTXR shares now costs nearly half the share price annually.
Availability has tightened to 48.4% — fewer than one share remains available for every two already lent out. A week ago, availability sat above 94%. The compression has been swift.
The ORTEX short score is 90.2 out of 100. That ranks among the most heavily shorted names on the platform.
On May 18, the put-call ratio jumped to 0.0852. The 20-day average is 0.030. That's a Z-score of 4.22 — an extreme reading by any measure.
A low PCR means calls dominate. Options traders are positioned heavily for upside. This came on the same day the stock fell 25%.
The divergence is stark. Short sellers are piling in. Options traders are buying calls. Both bets cannot be right.
Citius Pharmaceuticals reports today at 13:30 UTC. The timing makes the signals harder to read — but more urgent.
The last four earnings prints all moved the stock lower. The most recent, on May 15, sent shares down 26.8% in a single session. The stock is already down 25% from May 18 and off 39% over the past month.
HC Wainwright initiated coverage on May 18 with a Buy rating and a $4.00 price target. The stock closed at $0.527. That gap — over 650% upside to target — reflects analyst conviction in LYMPHIR's oncology pipeline, not near-term price momentum.
See the live data behind this article on ORTEX.
Open CTXR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
